WO2023115029A3 - Antibody-based depletion of il1r2-positive cells - Google Patents

Antibody-based depletion of il1r2-positive cells Download PDF

Info

Publication number
WO2023115029A3
WO2023115029A3 PCT/US2022/081854 US2022081854W WO2023115029A3 WO 2023115029 A3 WO2023115029 A3 WO 2023115029A3 US 2022081854 W US2022081854 W US 2022081854W WO 2023115029 A3 WO2023115029 A3 WO 2023115029A3
Authority
WO
WIPO (PCT)
Prior art keywords
il1r2
antibody
cell
depletion
positive cells
Prior art date
Application number
PCT/US2022/081854
Other languages
French (fr)
Other versions
WO2023115029A2 (en
Inventor
Melanie Angelika KLEINSCHEK
Susannah D. BARBEE
Bevin Marie SMITH
Original Assignee
Trex Bio, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trex Bio, Inc. filed Critical Trex Bio, Inc.
Publication of WO2023115029A2 publication Critical patent/WO2023115029A2/en
Publication of WO2023115029A3 publication Critical patent/WO2023115029A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Provided herein are antibodies that deplete IL1R2-positive (IL1R2+) cells. Antibodies disclosed herein bind the extracellular domain of membrane bound IL1R2 present on the surface of a cell and cause the depletion or killing of the cell. Also disclosed herein are methods to modulate an immune response by administering an IL1R2 inhibitor (e.g., an antibody). For example, such methods can include a method of enhancing an immune response in a subject, comprising administering an anti-interleukin 1 receptor 2 (IL1R2) antibody to the subject, wherein the anti-IL1R2 antibody binds to the extracellular domain of membrane-bound IL1R2 present on the surface of the cell and causes the depletion or killing of the cell.
PCT/US2022/081854 2021-12-18 2022-12-16 Antibody-based depletion of il1r2-positive cells WO2023115029A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163291375P 2021-12-18 2021-12-18
US63/291,375 2021-12-18

Publications (2)

Publication Number Publication Date
WO2023115029A2 WO2023115029A2 (en) 2023-06-22
WO2023115029A3 true WO2023115029A3 (en) 2023-09-14

Family

ID=86773649

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/081854 WO2023115029A2 (en) 2021-12-18 2022-12-16 Antibody-based depletion of il1r2-positive cells

Country Status (1)

Country Link
WO (1) WO2023115029A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109468380A (en) * 2018-10-31 2019-03-15 复旦大学附属肿瘤医院 IL1R2 is in Prognosis in Breast Cancer assessment and the application in targeted therapy
WO2021007569A1 (en) * 2019-07-11 2021-01-14 La Jolla Institute For Immunology Intratumoral tfr cells curtail anti-pd-1 treatment efficacy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109468380A (en) * 2018-10-31 2019-03-15 复旦大学附属肿瘤医院 IL1R2 is in Prognosis in Breast Cancer assessment and the application in targeted therapy
WO2021007569A1 (en) * 2019-07-11 2021-01-14 La Jolla Institute For Immunology Intratumoral tfr cells curtail anti-pd-1 treatment efficacy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARTIN PRAXEDIS, PALMER GABY, VIGNE SOLENNE, LAMACCHIA CÉLINE, RODRIGUEZ EMILIANA, TALABOT-AYER DOMINIQUE, ROSE-JOHN STEFAN, CHALA: "Mouse neutrophils express the decoy type 2 interleukin-1 receptor (IL-1R2) constitutively and in acute inflammatory conditions", JOURNAL OF LEUKOCYTE BIOLOGY, JOHN WILEY & SONS LTD., GB, vol. 94, no. 4, 1 October 2013 (2013-10-01), GB , pages 791 - 802, XP093092309, ISSN: 0741-5400, DOI: 10.1189/jlb.0113035 *

Also Published As

Publication number Publication date
WO2023115029A2 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
MX2021005008A (en) Multivalent regulatory t cell modulators.
WO2020092854A3 (en) Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
EA202190607A1 (en) CHIMERIC ANTIGENIC RECEPTOR FOR BCMA BASED ON SINGLE DOMAIN ANTIBODY AND ITS APPLICATION
PH12019550044A1 (en) Binding molecules that modulate a biological activity expressed by a cell
WO2020123691A3 (en) Chimeric antigen receptors and car-t cells and methods of use
AU2016298227A8 (en) PD-1-binding molecules and methods of use thereof
MY159517A (en) A monoclonal antibody and a method thereof
AU2018338418A1 (en) Anti-HLA-A2 antibodies and methods of using the same
WO2019005640A3 (en) Multi-specific antibodies and methods of making and using thereof
DE69637890D1 (en) MONOCLONAL ANTIBODY FOR THE INHIBITION OF HIV-1-HÜLLGYKOPROTEIN-MEDIATED MEMBRANE FUSION
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
WO2022031940A3 (en) Il28ra binding molecules and methods of use
NZ740474A (en) Antigen receptors and uses thereof
MX2021005323A (en) Methods of treating graves' ophthalmopathy using anti-fcrn antibodies.
MX2023008000A (en) B7h4-targeted antibody-drug conjugates and methods of use thereof.
MX2022013933A (en) Cell.
ZA202206438B (en) Single domain antibodies and chimeric antigen receptors targeting bcma and methods of use thereof
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
WO2022115641A3 (en) Antigen specific t cells and methods of making and using same
WO2023115029A3 (en) Antibody-based depletion of il1r2-positive cells
PE20232050A1 (en) ANTI-CD19 ANTIBODIES AND CAR-T STRUCTURES
CR20230245A (en) Gucy2c binding molecules and uses thereof
MX2022010360A (en) Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof.
MX2022005862A (en) Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies.
ZA202213707B (en) Bispecific antibody and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22908770

Country of ref document: EP

Kind code of ref document: A2